CBLL Stock Analysis: Buy, Sell, or Hold?
CBLL - CeriBell, Inc. Common Stock
$24.20
-0.11 (-0.45%)
▼
5d:
+3.73%
30d:
+48.65%
90d:
+29.14%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When CBLL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CBLL is 10.2% above its trading range ($21.96). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CBLL is 10.2% above its trading range ($21.96). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CBLL is currently trading at $24.20, which is considered extended relative to its 30-day fair value range of $17.10 to $21.96.
Technical Outlook: Technically, CBLL is showing sideways momentum. Immediate support is located at $18.64, while resistance sits at $25.33.
Market Sentiment: CBLL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.29 (+12.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CBLL is showing sideways momentum. Immediate support is located at $18.64, while resistance sits at $25.33.
Market Sentiment: CBLL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.29 (+12.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.10 -
$21.96
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
13.2%
All Signals
- BEARISH: Price significantly overextended (+10.2% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($27.29)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.10 -
$21.96
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$18.64
Resistance Level
$25.33
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.74
Wall Street Target
$27.29
(+12.8%)
Revenue Growth (YoY)
32.5%
Profit Margin
-64.7%
Share & Embed Analysis
Last updated: August 23, 2026 1:56 AM ET
Data refreshes hourly during market hours. Next update: 2:56 AM
Data refreshes hourly during market hours. Next update: 2:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CBLL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Xingjuan Chao
SELL
39000 shares
2026-04-06
Raymond Woo
SELL
11112 shares
2026-04-01
Rebecca B Robertson
SELL
827 shares
2026-03-03
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 37 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
